Celgene's Phase III POSTURE trial of Otezla fails to meet primary endpoint

US-based biotechnology firm Celgene has reported results from its Phase III POSTURE trial evaluating its oral, selective inhibitor of phosphodiesterase 4 (PDE4) 'Otezla', in patients with active ankylosing spondylitis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news